Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNIB0600A: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 18 evaluable patients with non-squamous NSCLC or platinum-resistant ovarian cancer showed that 1.8-2.8

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE